54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients
Liso-cel Earns FDA Accelerated Approval in R/R Follicular Lymphoma
Data from the TRANSCEND-FL trial support the accelerated approval of lisocabtagene maraleucel in relapsed/refractory follicular lymphoma.
Pre-Transplant FLT3-ITD Detection Confers Relapse/Death Risk in AML
Alternative treatment strategies may be necessary for a high-risk population of patients with acute myeloid leukemia and residual FLT3-ITD.
FDA Grants Breakthrough Therapy Designation to Petosemtamab in HNSCC
Data from a phase 1/2 trial support the FDA breakthrough therapy designation for petosemtamab in recurrent head and neck squamous cell carcinoma.
FDA Approves HPV Self-Collection Solution for Cervical Cancer Detection
Approval of the self-collection solution may reduce barriers to sample collection and increase access to cervical cancer screening.
Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT Trial
Determining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.
Higher Mortality Risk Reported in Cancer Surgery During COVID-19 Pandemic
Patients with cancer who underwent surgery during the COVID-19 pandemic were also more likely to have respiratory complications.
55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left Breast Cancer
Investigators Discontinue Vibostolimab Combo in Resected Melanoma Trial
The phase 3 KeyVibe-010 trial is unlikely to meet its primary end point of recurrence-free survival due to a high rate of treatment discontinuation.
Complementary and Alternative Medicine in Cancer Care: Does It Have a Role?
While treatment centered around multiple drug options is common practice in oncology, the use of complementary and medicine alternative medicine is being introduced in the space.
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer
Nivolumab ± Ipilimumab Yields Durable Responses in Cervical Cancer
The CheckMate 358 trial assessed various doses of nivolumab with or without ipilimumab for recurrent or metastatic cervical cancer.
57 Addressing Barriers to Identifying Patients With HER2-Low Metastatic Breast Cancer in a Large Community Oncology Practice
Nivolumab Combo Does Not Meet PFS End Point in Unresectable NSCLC
The progression-free survival end point was not met in the CheckMate -73L trial assessing patients with unresectable stage III non–small cell lung cancer.
Leveraging Surgical Oncology Advances in Colorectal Cancer Care
Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.
Lifileucel Yields Responses in Metastatic Non–Small Cell Lung Cancer
Phase 2 data support additional investigation of lifileucel as a treatment for patients with metastatic non–small cell lung cancer.
58 Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients
Nivolumab Meets ORR/PFS24 End Points in dMMR Uterine and Ovarian Cancer
Although the sample size for this trial was small, data still highlight a potential benefit with nivolumab in dMMR uterine and ovarian cancers.
59 Acceptability of Microbiome Sampling-Based Surgical Oncology Research in Minority Breast Cancer Patients
Nivolumab Combo Shows Efficacy, Safety in Muscle-Invasive Bladder Cancer
Phase 2 data support the potential of replacing cisplatin with nab-paclitaxel as a backbone therapy for those with muscle-invasive bladder cancer.
60 Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer in the United States by Palliative Care Utilization
FDA Grants Fast Track Designation to SNB-101 in Small Cell Lung Cancer
Treatment with SNB-101 previously demonstrated tolerability among patients with solid tumors in a phase 1 trial.
61 High-Risk Screening Compliance in Women Diagnosed With Breast Cancer and a History of Thoracic Radiation Prior to Age 30
Six-Year Imatinib Maintenance Therapy Reduces Recurrence Risk in GIST
Investigators found that imatinib maintenance therapy for 6 years reduced the risk of recurrence in patients with gastrointestinal stromal tumors.
Fuzuloparib ± Apatinib Improves PFS in BRCA+ Metastatic Breast Cancer
Phase 2 data support the use of fuzuloparib with or without apatinib in HER2-negative metastatic breast cancer harboring BRCA1/2 germline mutations.
Pembrolizumab Combo Does Not Reach DFS End Point in Endometrial Cancer
Developers will work with investigators of the phase 3 KEYNOTE-B21 trial to share their findings with the scientific community.
62 The Impact of Genomic Assays on Breast Cancer Systemic Therapy Treatment Decisions in a Mostly Black Patient Population
Nivolumab Combo Significantly Boosts Survival in Urothelial Carcinoma
Findings from the CheckMate-901 study support the use of frontline nivolumab plus gemcitabine/cisplatin in advanced urothelial carcinoma.
63 Choice Architecture Bias in Genetic Counseling of Breast Cancer Patients
Setanaxib/Pembrolizumab Improves Survival in Head and Neck Cancer
Phase 2 data also highlight an improvement in disease control rate with setanaxib/pembrolizumab in squamous cell carcinoma of the head and neck.